Zilebesiran: large blood pressure falls, wide intervals, and a hint of fade

Design

systematic review and meta-analysis of 4 randomised controlled trials, random-effects model, RoB 2.0

Population

1,412 adults with mild to moderate hypertension

Primary outcome

placebo-adjusted change in office systolic blood pressure

Effect

−7.16 mmHg (95% CI −13.63 to −0.70); 24-hour ambulatory systolic −9.92 mmHg (−18.74 to −1.10); adverse events OR 1.46

Four randomised trials, 1,412 adults with mild to moderate hypertension, pooled with a random-effects model. Zilebesiran is an RNA interference therapy directed at angiotensinogen, given by injection at long intervals. The placebo-adjusted fall in office systolic pressure was 7.16 mmHg (95% CI −13.63 to −0.70). Ambulatory measures moved further: 24-hour systolic −9.92 mmHg (−18.74 to −1.10), nighttime systolic −9.95 mmHg (−16.71 to −3.19), 24-hour diastolic −7.27 mmHg (−11.13 to −3.41). Angiotensinogen fell markedly, as the mechanism predicts.

Two things temper this. A subgroup analysis by follow-up duration found the daytime systolic reduction significantly greater at three months than at six (P = 0.02), which suggests the effect attenuates within a dosing interval rather than holding flat. And adverse events were commoner than placebo overall (OR 1.46), driven by hyperkalaemia and injection-site reactions, though serious adverse events did not differ.

The appeal of a twice-yearly injection for hypertension is obvious in any practice where adherence is the limiting factor, and that includes most of Indian primary care. But every comparison here is against placebo, in small trials, in mild to moderate hypertension. Nothing yet says how it performs against a cheap generic combination taken reliably.

• Watch for active-comparator trials before forming a view — placebo-controlled data cannot position a new antihypertensive
• Note the hyperkalaemia signal; a drug that suppresses angiotensinogen for months cannot be stopped quickly if potassium rises
• The nighttime systolic effect is the most consistent of the set and is the measure most tied to outcome
• No cardiovascular outcome data exist for this agent

Why it matters

A twice-yearly injection would change who stays controlled — but only if the effect lasts the interval, and this analysis suggests it may not.

Don't overread it

Subgroup comparison by follow-up duration is exploratory; attenuation is a hypothesis these data raise, not a demonstrated waning.

The statistics, in plain English

The office systolic interval runs from −13.63 to −0.70 mmHg. The upper end is a fall too small to matter clinically, so 'significant' here means only that zero is excluded — the data are compatible with anything from a trivial effect to a large one. Pooling four small trials produces intervals this wide; the ambulatory estimates are larger but no more precise.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.